Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 656 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading MOST POPULAR Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... August 25, 2020 Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... July 9, 2021 New on NCI’s Websites for June 2022 June 10, 2022 Load more HOT NEWS Texas Baby Is Born With Almost No Skin On His Body,... Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel... NF1 Associated with More Cancer Types Than Previously Known
